Legend Biotech (LEGN) Receivables - Other (2019 - 2025)

Legend Biotech (LEGN) has reported Receivables - Other for 7 consecutive years, with $1.2 million the latest figure, recorded in Q3 2025.

• Quarterly Receivables - Other fell 38.71% year-over-year to $1.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $1.2 million (down 38.71% YoY) and the FY2024 annual result came in at $780000.0, down 1.27% from the prior year.
• Receivables - Other improved to $1.2 million in Q3 2025 per LEGN's latest filing, from $1.0 million in the prior quarter.
• Over the last five years, Receivables - Other for LEGN reached as high as $50.0 million in Q4 2021 and fell as low as $46000.0 in Q2 2021.
• A 5-year average of $12.0 million and a median of $1.1 million in 2024 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2022 — Receivables - Other plunged 98.1% — and 2024, when it slipped 1.27%.
• Year by year, Receivables - Other stood at $50.0 million in 2021, then tumbled by 98.1% to $948000.0 in 2022, then slipped by 16.67% to $790000.0 in 2023, then dropped by 1.27% to $780000.0 in 2024, then soared by 49.62% to $1.2 million in 2025.
• According to Business Quant data, Receivables - Other over the past three periods registered $1.2 million, $1.0 million, and $954000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.